Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Marshalls cuts divi as profits fall, but outlook improves

(Sharecast News) - Landscaping, building, and roofing products group Marshalls has trimmed its dividend after a dip in profits in 2024, but pointed to a recovery in end-markets later this year. The company said its confidence is supported by the government's ambition to "reinvigorate" new house building and invest in infrastructure, bolstered by further reductions in interest rates.

Marshalls reported revenues of £619.2m, down 8% on 2023, with the smaller landscaping division seeing a 17% drop in sales due to lower volumes, price pressures in the industry and a disposal in Belgium.

Revenues in building and roofing, which together account for 80% of group sales, fell 3% and increased 4%, respectively.

The company said a focus on efficiency gains and cost reduction helped limit the decline in adjusted pre-tax profit to 2% to £52.2m.

"I am pleased to report our results for what has been an important year for Marshalls, where the group has shown resilience in challenging markets by restricting the reduction in profit before tax to two per cent despite an eight per cent contraction in revenue," said chief executive Matt Pullen.

Nevertheless, in line with the group policy of covering dividend twice by adjusted earnings, the company reduced its final dividend by 5% to 5.4p per share, taking the full-year payout to 8.0p, down 4% on the year before.

Looking ahead, Marshalls expects landscaping to return to growth in 2025, along with roofing and building.

"The group is well positioned to respond swiftly to improving activity levels as key end markets recover and the board remains confident about delivering a material increase in profitability and returns over the medium-term," Marshalls said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.